The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma

Conclusions Ponatinib reduces neuroblastoma cell viabilityin vitro and reduces tumor growth and vascularityin vivo. The antitumor effects of ponatinib suggest its potential as a novel therapeutic agent for neuroblastoma, and further preclinical testing is warranted.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research